Navigation Links
U of M researcher examines newly emerging deadly disease

Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus. The infection then moves to the lungs, making superantigens (bacterial toxins that activate large numbers of T cells), often leading to death due to hypertension and shock. Purpura fulminans has been identified in five cases in the Minneapolis-St. Paul, Minn., metropolitan area during 2000-2004, as described in the April 1, 2005 issue of Clinical Infectious Diseases. This new disease has also been determined in seven additional cases nationwide. Of the 12 known cases, only two patients have survived.

Purpura fulminans is an acute illness commonly associated with meningococcemia or invasive streptococcal disease, and it is typically characterized by the depletion of clotting factors in the blood and skin lesions. Purpura fulminans refers to widespread severe purpura with extensive tissue damage and sloughing of skin. Purpura are skin lesions that may be many centimeters in diameter caused by the leakage of blood into the skin.

"It is important to alert medical professionals about the symptoms and treatments of this new deadly disease," said Patrick Schlievert, Ph.D., professor of microbiology at the University of Minnesota Medical School. "We are continuing to study and monitor cases of purpura fulminans to better understand the causes and best treatment options."

On the basis of experience, the University of Minnesota experts have identified three recommended treatments for purpura fulminans. Patients who present symptoms of purpura should receive antibiotic therapy not only against Neisseria meningitidis and streptococci, but also against methicillin-resistant S. aureus (MRSA), with the consideration that the staphylococcal disease may be more common than the two prior illnesses. Patients should also be given early admi nistration of activated protein C (i.e., drotrecogin) in an attempt to minimize purpuric skin injury and to slow the inflammatory cascade before irreparable tissue injury occurs. In addition, because toxic shock syndrome is mediated by superantigens, it is possible that intravenous immunoglobulin therapy may be indicated. Of the five patients observed in the Minneapolis-St. Paul area during the period of 2000-2004, four of the patients were previously healthy and four of the patients were women. Schlievert and colleagues hypothesize that the clinical features of purpura fulminans and toxic shock syndrome seen in these patients resulted from massive cytokine release induced by the S. aureus strains.


'"/>

Source:University of Minnesota


Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... 19, 2017 Sensory Inc ., ... security for consumer electronics, and i ... and cybersecurity solutions, today announced a global partnership ... institutions worldwide to bolster security of data sensitive ... user authentication platforms they offer, innerCore now offers ...
Breaking Biology News(10 mins):
(Date:2/18/2017)... 2017 Research and Markets has announced the ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... Rest of World. Annual estimates and forecasts are provided for the ... for these markets. Market data and analytics are derived from primary ...
(Date:2/17/2017)... Calif. , Feb. 17, 2017  Protagonist ... detailing data on its oral peptide drug candidates, ... Congress of the European Crohn,s and Colitis Organization ... Barcelona, Spain from February ... posters detail preclinical data on Protagonist drug candidates ...
(Date:2/16/2017)... Fla. , Feb. 16, 2017  MDNA ... revolutionizing the development of liquid biopsy tests based ... entered into an exclusive license agreement with its ... MDNA,s proprietary liquid biopsy test for prostate cancer, ... South Korea . This is the first ...
(Date:2/16/2017)... PALM BEACH, Florida , February 16, 2017 ... vastly improving with the infusion of innovative telemedicine ... patient monitoring services that are experiencing a boom ... evolve with the advancement of technologies, services and ... Technologies Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, ...
Breaking Biology Technology: